Expression Analysis has hired Jeff Fitzgerald as director of business development. Fitzgerald has more than ten years of sales and support experience with Affymetrix and RainDance Technologies.
Expression Analysis has appointed Jeff Fitzgerald as director of business development.
This story was originally published Aug. 8.
Expression Analysis is now a certified service provider of Agilent's SureSelect target enrichment kit, the companies said this week.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agilent Technologies today announced that Expression Analysis is now a certified service provider for its SureSelect Target Enrichment System for next-generation sequencing.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
PacBio is recommending EA as its North American service provider for the pharmaceutical market.
The deal gives Quintiles access to PGT’s genomic data-analysis technology, and is in line with Quintiles' ongoing efforts to expand its pharmacogenomics research capabilities.
The companies' first project will be a renal cancer clinical trial for an undisclosed Quintiles client. The partners aim to identify genetic markers that are predictive of adverse events and efficacy.
The firms will jointly identify opportunities to apply large-scale genomic analyses to test clinical hypotheses and correlate biomarkers of disease prognosis and drug responsiveness.
I-SPY 2 is using genetic and other biomarkers to develop and evaluate breast cancer therapies more cheaply and quickly than current methods.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.